Corwin Brink
Psychiatry · Lodi, CANPI 1356451793
Payments from drug & device makers
Across 428 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lundbeck LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Otsuka America Pharmaceutical, Inc.$917
- Sunovion Pharmaceuticals Inc.$764
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$354
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,460100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,053 |
| Lundbeck LLC | 54 | $1,046 |
| Takeda Pharmaceuticals U.S.A., Inc. | 79 | $1,003 |
| Otsuka America Pharmaceutical, Inc. | 42 | $917 |
| Sunovion Pharmaceuticals Inc. | 47 | $764 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $354 |
| Tris Pharma Inc | 11 | $275 |
| Vanda Pharmaceuticals Inc. | 8 | $237 |
| Johnson & Johnson | 12 | $236 |
| Idorsia Pharmaceuticals US Inc | 13 | $202 |
| Alkermes, Inc. | 9 | $201 |
| Ironshore Pharmaceuticals Inc. | 9 | $183 |
| Neurocrine Biosciences, Inc. | 8 | $174 |
| Supernus Pharmaceuticals, Inc. | 8 | $151 |
| Shire North American Group Inc | 9 | $124 |
| Axsome Therapeutics, Inc. | 4 | $103 |
| Almatica Pharma LLC | 4 | $94 |
| Teva Pharmaceuticals USA, Inc. | 4 | $77 |
| Alfasigma USA, Inc. | 3 | $75 |
| Bausch Health US, LLC | 4 | $67 |
| Avanir Pharmaceuticals, Inc. | 2 | $49 |
| Corium, LLC | 1 | $31 |
| Eisai Inc. | 1 | $18 |
| Neuronetics, Inc. | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$125
How this compares
$7,468 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FetzimaLevomilnacipran Hcl | 20 | $9,864 |
| KlonopinClonazepam | 13 | $1,859 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 17 | $1,789 |
| Aripiprazole | 50 | $1,185 |
| Bupropion XlBupropion Hcl | 66 | $1,158 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 53 | $1,101 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 28 | $1,068 |
| Lamotrigine | 39 | $1,032 |
| Alprazolam | 83 | $1,024 |
| Olanzapine | 25 | $942 |
| Eszopiclone | 12 | $705 |
| Duloxetine Hcl | 20 | $674 |
| Lithium Carbonate | 16 | $598 |
| Sertraline Hcl | 55 | $560 |
| Escitalopram Oxalate | 26 | $528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieFetzima | $1,053 | $9,86420 claims |
| Almatica Pharma LLCSertraline Hcl | $94 | $56055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Lodi
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.